Jose Pablo Werba
Overview
Explore the profile of Jose Pablo Werba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arca M, Averna M, Borghi C, Lettino M, Filardi P, Alberti A, et al.
G Ital Cardiol (Rome)
. 2023 Sep;
24(10):770-780.
PMID: 37767829
Atherosclerotic cardiovascular diseases remain the main cause of mortality worldwide, due to a poor control of modifiable risk factors for atherosclerosis. High levels of low-density lipoprotein cholesterol represent the most...
2.
Amadio P, Porro B, Cavalca V, Zara M, Eligini S, Sandrini L, et al.
Int J Cardiol
. 2023 Aug;
390:131229.
PMID: 37527756
Background: Takotsubo cardiomyopathy (TTS) has long been considered a benign condition, despite recurrent events and long-term adverse outcomes are often reported. Endothelial damage, blood hyperviscosity, and platelet activation described in...
3.
Baldassarre D, Iacoviello L, Baetta R, Roncaglioni M, Condorelli G, Remuzzi G, et al.
BMJ Open
. 2023 Jul;
13(7):e072040.
PMID: 37451717
Introduction: Prevention of cardiovascular disease (CVD) is of key importance in reducing morbidity, disability and mortality worldwide. Observational studies suggest that digital health interventions can be an effective strategy to...
4.
Romandini A, Baldassarre D, Genovese S, Capri S, Pompilio G, Scatigna M, et al.
Pharmaceuticals (Basel)
. 2023 Jun;
16(2).
PMID: 37259324
Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive...
5.
Poli A, Catapano A, Corsini A, Manzato E, Werba J, Catena G, et al.
Nutr Metab Cardiovasc Dis
. 2022 Dec;
33(2):245-257.
PMID: 36566123
Aims: Although adequate clinical management of patients with hypercholesterolemia without a history of known cardiovascular disease is essential for prevention, these subjects are often disregarded. Furthermore, the scientific literature on...
6.
Lanza O, Cosentino N, Lucci C, Resta M, Rubino M, Milazzo V, et al.
J Clin Med
. 2022 Sep;
11(18).
PMID: 36142948
Background: Prior statin therapy has a cardioprotective effect in patients undergoing elective or urgent percutaneous coronary intervention (PCI). However, data on patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI...
7.
Eligini S, Porro B, Werba J, Capra N, Genovese S, Greco A, et al.
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740426
The effects of the oral glucose tolerance test (OGTT) on red blood cells (RBCs) have not been thoroughly investigated, although it is known that the ingestion of 75 g of...
8.
Gorini A, Galli F, Giuliani M, Pierobon A, Werba J, Palazzo Adriano E, et al.
J Pers Med
. 2022 Jan;
12(1).
PMID: 35055353
During an acute cardiac event, Takotsubo Syndrome (TTS) and Acute Coronary Syndrome (ACS) apparently share very similar clinical characteristics. Since only a few inconsistent studies have evaluated the psychological features...
9.
Giroli M, Werba J, Rise P, Porro B, Sala A, Amato M, et al.
Nutrients
. 2021 Aug;
13(7).
PMID: 34371898
The Mediterranean diet (MD) prevents cardiovascular disease by different putative mechanisms, including modifications in the blood fatty acid (FA) profile. Polytherapy for secondary cardiovascular prevention might mask the effect of...
10.
Werba J, Bonomi A, Giroli M, Amato M, Vigo L, Agrifoglio M, et al.
Eur J Prev Cardiol
. 2021 Feb;
29(7):997-1004.
PMID: 33624003
Aims: Patients with coronary heart disease (CHD) are at very high risk of recurrent events. A strategy to reduce excess risk might be to deliver structured secondary prevention programmes, but...